CytoDyn Inc.

CYDY ·Healthcare, Drug Manufacturers - General, United States
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2026 FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
Operating Activities
Net Income $-42.7M $3.7M $-49.8M $-79.8M $-210.8M $-176.5M $-139.9M $-56.2M
Depreciation & Amortization $17.0K $18.0K $29.0K $175.0K $781.0K $1.8M $2.0M $1.2M
Depreciation — — $29.0K $43.0K — — — —
Amortization — — — $100.0K $700.0K $1.8M $2.0M $1.2M
Stock-Based Compensation $1.6M $1.6M $2.4M $4.3M $6.2M $10.4M $6.5M $3.4M
Net Cash from Operating Activities $-17.3M $-8.8M $-11.0M $-25.1M $-77.7M $-117.6M $-68.8M $-50.5M
Investing Activities
Capital Expenditures — — — — — $122.0K $41.0K $26.0K
Business Acquisitions — — — — — — — —
Net Cash from Investing Activities $0 $0 — — — $-122.0K $-41.0K $-45.0K
Financing Activities
Dividends Paid — — — — — — — —
Stock Repurchases — — — — — — — —
Net Cash from Financing Activities $17.2M $10.9M $11.7M $29.9M $48.0M $137.3M $79.7M $52.7M
Net Change in Cash $-51.0K $2.1M $766.0K $4.8M $-29.7M $19.7M $10.8M $2.2M
Free Cash Flow — — — — — $-117.7M $-68.8M $-50.5M
← Newer Page 1 of 2 Older →